Psychiatry Product Review - Aripiprazole modified release for schizophrenia

Abilify Maintena® represents an important treatment option for schizophrenia. This review discusses the evidence in support of the use of this antipsychotic LAI.

Independent specialist expert commentary provided by Professor David Jonathan Castle and Associate Professor James Scott.

Please login below to download this issue (PDF)

Subscribe